The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Distribution Update

27 Jun 2005 06:00

Embargoed: 27 June 2004 Akers Biosciences, Inc. ("Akers" or the "Company") Re. UK Distribution Agreement Akers Biosciences, Inc. is pleased to announce the launch of a number of itsproducts in the UK through its UK distribution agent Advanced Rapid DiagnosticsLimited ("ARD"). ARD was established in order to penetrate the UK markets withAkers' growing range of products.The Company is already actively marketing a number of CE approved products inthe UK through ARD which, among others, include:Tests for `drugs of abuse'Akers has developed a suite of tests for `drugs of abuse' including tests foruse of methadone, heroine, cocaine, marijuana and ecstasy among others. Forthis product ARD is targeting the public service markets alongside retailbusinesses or, indeed, any organisation wishing to have the ability to performrapid tests on staff. The Company believes that there is significant potentialfor law enforcement agencies or educational establishments to adopt thesetests.Alcohol BreathalyzersARD is marketing Akers' range of alcohol breathalyzers in the UK to a range ofindustries, in particular transport businesses operating any form of vehicles,be they rail, air, road or sea. In addition to ensuring transportation safety,the use of these products may also positively impact insurance costs for thesebusinesses. ARD will also be looking to penetrate retail markets including highstreet pharmacies so that the public will have access to affordable tests toshow alcohol levels, with particular emphasis on self-regulation in the case ofdriving.PIFA‚® Heparin/PF4 test for heparin-induced thrombocytopenia and thrombosissyndrome (HITTS)Following increasing levels of penetration in the United States and Canada forthis test, the first rapid test for heparin/platelet factor-4 antibodies, ARDwill be initially targeting the private healthcare sector in the UK. Heparin isa widely used intravenous anticoagulant in the United Kingdom. Intravenousheparin is commonly used for the prophylaxis and treatment of thromboembolicdisease, as well as numerous other applications including certain types of lungand heart disorders, and during or after a variety of surgeries including openheart, bypass, dialysis and orthopedic procedures. Heparin is also used fordiagnostic and therapeutic interventional radiologic procedures. Akers' test isable to identify, almost instantly, patients at risk for developing HITTS as aresult of administering of heparin. This is particularly crucial in cases ofemergency surgery. Patients identified by the test as being at risk can beprescribed alternative drugs in order to avoid, potentially, fatal reactions toheparin.Cholesterol TestsBlood cholesterol consists of HDL cholesterol (often called "good cholesterol")and LDL cholesterol (often called "bad cholesterol"). The risk of heart diseaseis related to HDL levels, total cholesterol levels, and other risk factors. TheAkers Biosciences Tri-Cholesterol Test Kit is the only FDA-approved rapid assaythat provides a complete cholesterol profile of the patient, withsemi-quantitative determinations of high-density lipoprotein (HDL) cholesterol,low-density lipoprotein (LDL) cholesterol, and total cholesterol levels inwhole blood obtained from a finger stick. The test is designed for routinemonitoring of cholesterol levels right in a physician's office or directly athome.Dr. Raymond Akers, Chief Executive, Akers Biosciences, Inc. commented,"We are now enjoying very encouraging levels of sales for many of our productsin the United States and other parts of the world and I am delighted to beembarking upon an aggressive marketing and sales drive in the UK. As is thecase in the US, many of our products will be completely unique in the UK,enabling crucial tests to be performed rapidly and accurately. There is agrowing need for tests for alcohol levels and use of drugs of abuse all overthe world. Our tests in this area will enable people, particularly in thetransport and education industries to identify situations of abuse instantly.As for our PIFA Heparin PF-4 test, we believe this test will help save lives inthe UK. In addition, the medical industry can save millions of pounds inheparin-related law suits of patients who have suffered symptoms of a drugwhose prescription could have been avoided through identification of risk withour test and the prescription of an alternative."Dr. Raymond AkersChief Executive, Akers Biosciences, Inc.Tel. 020 7917 9476Barry ParkerChief Executive, Advanced Rapid Diagnostics LimitedTel. 0161 792 1112Ben SimonsHansard CommunicationsTel. 020 7245 1100ENDAKERS BIOSCIENCES INC
Date   Source Headline
10th Dec 201210:39 amRNSNotice of AGM
26th Nov 20127:00 amRNSDistribution Partnership Forged in China
22nd Oct 20127:00 amRNSIssue of Equity
8th Oct 201212:00 pmRNSHolding(s) in Company
17th Sep 20127:00 amRNSPrivate Placing
17th Sep 20127:00 amRNSHalf Yearly Report
28th Jun 20127:00 amRNSFinal Results
30th Mar 201210:06 amRNSHolding(s) in Company
27th Feb 20125:01 pmRNSDirectorate Change
6th Jan 20127:00 amRNSTrading Update
6th Dec 20117:00 amRNSLaunch of PIFA PLUSS PF4 Rapid Assay
7th Sep 20117:00 amRNSHalf Yearly Report
24th Aug 20117:00 amRNSClinical Trials Commenced: COPD Rapid Assay
30th Jun 20117:00 amRNSUS$3.2 Million Purchase Order for Revelar
10th May 20115:54 pmRNSResult of AGM
28th Apr 20113:41 pmRNSAnnual Report & Accounts & AGM Notice
27th Apr 20117:00 amRNSUS patent protection grant
18th Apr 20117:00 amRNSAsthma Breath Test - Clinical Trials
11th Apr 20117:02 amRNSFinal Results
11th Apr 20117:00 amRNSSupply Agreement & Technology Acquisition
8th Apr 20117:00 amRNSConclusion of HIT Study
16th Mar 20117:00 amRNSPatent Protection - Rapid Blood Cell Separator
2nd Mar 20114:20 pmRNSHolding(s) in Company
28th Feb 20117:00 amRNSTotal Voting Rights
14th Feb 20113:08 pmRNSTR-1 Notification of Major Interest in Shares
14th Feb 20112:57 pmRNSTR-1 Notification of Major Interest in Shares
10th Feb 20117:00 amRNSIssue of Equity & Director Shareholding
1st Feb 20117:00 amRNSPlacing
14th Jan 20117:00 amRNSBreathScan PRO Receives Regulatory Clearance
5th Jan 20117:00 amRNSTrading Statement
29th Dec 20107:00 amRNSOrder for Tri-Cholesterol Tests - Middle East
16th Nov 20101:14 pmRNSIssue of Equity
30th Sep 20103:57 pmRNSHalf Yearly Report
29th Sep 20107:00 amRNSPIFA Heparin/Platelet Factor-4 - New Data
6th Sep 20107:00 amRNSProduct Distribution Expansion: Middle East/India
12th Aug 20107:00 amRNSFurther Distribution Agreement - PIFA Heparin/PF4
21st Jul 20105:18 pmRNSResult of AGM
21st Jun 20107:00 amRNSFinal Results
18th Jun 20107:00 amRNSBreath Ketone Test - Positive Data
14th Jun 20107:00 amRNSUSA Distribution Agreement
9th Jun 20107:00 amRNSBreathScan Alcohol Detection - Product Extension
26th Mar 20104:52 pmRNSHolding(s) in Company
19th Mar 20101:00 pmRNSChange of Adviser
17th Mar 20107:00 amRNSBreathScan Licensing Agreement - UK & Ireland
16th Mar 20107:00 amRNSClinical Study Data - PIFA Heparin
18th Feb 20109:04 amRNSDirector/PDMR Shareholding
30th Dec 20097:00 amRNSDirectorate Change
17th Dec 20099:23 amRNSHolding(s) in Company
15th Dec 20097:00 amRNSABI Obtains GSA Contract
4th Dec 20097:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.